Abstract: There has recently been remarkable progress in immunosuppressive agents, such as tacrolimus and cyclosporine. Therefore, the rate of organ establishment has improved in transplantation. However, immunosuppressive agents generally suppress the function of T cells. Thus, opportunistic infections, such as cytomegalovirus infection, are still a major problem in kidney transplantation. Induction of specific tolerance to avoid immunosuppressive drug therapy after kidney transplantation is considered as the ultimate goal of transplantation. Various factors induce tolerance that involves establishment of hematopoietic chimerism and various cell subsets. In particular, we have carried out various studies regarding the cyclophosphamide-induced tolerance system. Tolerance is induced after establishment of hematopoietic chimerism after donor bone marrow transplantation. At the clinical stage, kidney transplantation before administration of cyclophosphamide after transfusion of bone marrow to create hematopoietic chimera is considered to be one of the most successful protocols. Furthermore, recent studies have shown the involvement of multiple populations of immune cells in preserving immunological tolerance and promoting long-term renal grafts. The present review focuses on how cyclophosphamide and other immune factors induce tolerance in kidney transplantation.
Introduction
Kidney transplantation is a suitable treatment for patients with end-stage renal disease. 1 The majority of patients with renal transplants require life-long immunosuppressive therapy. Although immunosuppressive therapy has decreased the rate of acute graft loss and improved long-term graft survival, the side-effects of immunosuppressive drugs, such as infection, malignancy and cardiovascular disease, remain a major problem. 2 Therefore, induction of specific tolerance to avoid long-term immunosuppressive therapy after kidney transplantation is considered to be a goal of transplantation. Tolerance ensures that destructive immune responses after transplantation do not occur without systemic immunosuppressive agents.
Many attempts at the induction of chimerism for tolerance have been made in both basic research and clinical trials. 3, 4 After the trials, the chimerism-based approach through donor hematopoietic stem cell transplantation has been one of the important approaches to date that induced allograft tolerance in humans. Reduced intensity transplant approaches in the preclinical models using CY show that mixed chimerism was essential to the development of tolerance in HLA mismatched transplantation, although the chimerism was transient. 5, 6 After that, the results of various research have shown that chimerism need not be durable. 4, 7 CY has been known to be one of the strategies to achieve transient mixed chimerism.
We have previously carried out various studies regarding the CY-induced tolerance system. [8] [9] [10] [11] [12] As described below, CY is known to be one of the strategies to achieve mixed chimerism in this system. However, because recent articles also called this model a "CY-induced tolerance system," we also would like to call it the same. 13, 14 In these studies, destruction (not deletion) of donor-reactive T cells of recipient origin and recipient-reactive T cells of donor origin occur in the induction phase. Stable mixed chimerism has induced tolerance to skin allografts in H-2 identical mice. Destruction of donor-reactive T cells of recipient origin is considered to allow space for donor cells to expand in recipients, resulting in establishment of mixed chimerism. However, to prove the space, the further experiments are required. Using various preclinical data, including our data, the Massachusetts General Hospital research group undertook the challenging task of achieving tolerance in humans. They first reported establishment of kidney transplantation after donor hematopoietic SCT, which was conditioned using CY, to establish mixed chimerism. 15 More recently, combined kidney and BMT to establish mixed or full donor chimerism has achieved graft-specific tolerance. [16] [17] [18] [19] [20] Although establishing a mixed chimerism is very important for immune tolerance, much attention has been focused on various types of immune cells, which are important for tolerance. Immune cells, such as Tregs and NK T cells, play key roles in CYinduced tolerance and long-term survival of grafts.
Preclinical experiments of CY-induced tolerance
First of all, we should explain "tolerance." Tolerance has two aspects. The first one is tolerance against a self-antigen, whereas the second one is tolerance against an alloantigen. Tolerance against a self-antigen is further divided to central and peripheral tolerance. Thymocytes that express TCRs with a low affinity for self-peptide MHC complexes are positively selected to differentiate further in adaptive immunity. 21 Clonal deletion and diversion (differentiation to Tregs) mainly take place in the thymus, which eliminates or controls self-reactive T cells. This is called as "central tolerance." Although they are thought to be sufficient, they cannot control self-reactivity in the whole body. 21 Thus, "peripheral tolerance" processes exist. Generally, self-reactive T cells become functionally unresponsive (anergic) or are deleted after encountering selfantigens outside of the thymus by Tregs and cytokines. Induction of tolerance against a self-antigen has been attempted experimentally using several methods. However, researchers have not been able to prove these mechanisms for a long time.
In the 1980s, clonal deletion in the thymus was shown in a murine model. 22, 23 Mls-P is a so-called "super-antigen" that combines with MHC class II molecules. These ligands activate whole T cells families through Vb segments of the TCR. By using monoclonal antibodies against these TCRs, T cells with such TCRs that are reactive to self MIs antigens were able to be detected in the immature population of thymocytes, although these reactive cells have not been detected among mature thymocytes and peripheral blood. Therefore, T cells have been proven to be deleted during their differentiation in the thymus. This report first explained self-tolerance. 22, 23 Although many investigators have reported tolerance against an alloantigen, establishment of mixed (or full) chimerism in each approach is considered to be important. 21 Mixed chimerism is defined as engraftment of donor hematopoietic stem cells in the recipient body, leading to coexistence of both donor and recipient leukocytes. MacDonald et al. reported that neonatal tolerance was induced by the clonal deletion of alloreactive T cells in the thymus. 24 In contrast, Qin et al. raised the possibility that clonal anergy induced tolerance by using monoclonal T cells antibody. 25 Through the reports, the mechanism of tolerance against all-antigen gradually has become clear. Furthermore, we have used a system to show clonal destruction and peripheral clonal deletion in the CY-induced tolerance system. 8, [26] [27] [28] [29] We have also carried out a series of studies regarding non-myeloablative allogeneic SCT. This system is based on CY-induced tolerance, and consists of intravenous injection of allogeneic bone marrow and spleen cells, which is followed by intraperitoneal injection of CY. In this system, CY promotes the destruction of donorreactive T cells of recipient origin and recipient-reactive T cells of donor origin. Mixed chimerism was established in the presence of tolerance to skin allografts (Figs 1a, 2). This method is effective for all MHC-identical strain combinations. However, the method does not induce tolerance between strains with differing MHCs and minor antigens. The protocol involves injection of an anti-T-cell monoclonal antibody on day À1, donor bone marrow cells and spleen cells on day 0, and CY on day 2. 30 It is very important that CY is given after infusion of allogeneic bone marrow cells. In our previous study, three mechanisms that established tolerance were as follows: (i) peripheral alloreactive T cells were destroyed by CY administration; (ii) tolerance in the periphery permitted development of intrathymic donor hematopoietic chimerism and clonal deletion of thymocytes reactive to donor cells; and (iii) late after induction of tolerance, there is a breakdown in clonal deletion of alloreactive thymocytes (Fig. 1b) . [30] [31] [32] [33] Importantly, as discussed below, this system is called "PTCY" and has recently been the focus at the clinical stage.
Furthermore, we established a model for treatment of malignancy, by modifying our CY-induced tolerance system. 34 By the addition of donor lymph node cells 1 day after CY treatment, the ratio of mixed chimerism increases, although mild GVHD occurs compared with our tolerance system without donor lymphocyte infusion (Fig. 3) . Another remarkable feature of our study was clear induction of antitumor activity with low levels of mixed chimerism of donor cells (Fig. 3) . At the clinical stage for treatment of malignancy, graft versus tumor activity is thought to be associated with the degree of GVHD and chimerism. [34] [35] [36] [37] Although mild GVHD was observed in the group with donor lymphocyte infusion, our model system seems to be ideal, in regard to separating the GVHD from graft versus tumor activity.
The differential influence of CY on naive T cells and memory/effecter T cells has been reported previously. 38 The report showed resistance of donor memory/effecter T cells against CY administration in a murine model. At the clinical stage, it has been shown that donor non-alloreactive T cells provide the recipient with donor-derived immunity to fight infections. These cells also contribute to reconstitution of peripheral T cells in the long term, and recovery of T-cell and thymic functions after transplantation. In addition, the development of peripheral tolerance is considered to be the second step in the evolution of CY-induced tolerance. Clonal deletion and anergy as well as Tregs are important for the establishment of peripheral tolerance. 38 Although clonal destruction of alloreactive T cells has already been discussed above, the deletion is considered to be the dominant mechanism of CY-induced tolerance. However, the deletion is insufficient to explain peripheral tolerance in CY-induced tolerance system. Tregs also have an important role in CY-induced tolerance system. 39 The relevance of Tregs after CY was examined in several experimental models by our colleagues. 11, 40 In these studies, such suppressive cells were called "suppressor T cells," not Tregs. In MHC-mismatched combinations, the studies examined the role of Tregs in our model system of CY-induced tolerance. They examined the presence of a regulatory mechanism soon after allografting, and showed that administration of naive recipient splenocytes leads to rapid rejection of donor skin grafts in an established chimeric status. 11 In the report, adoptive transfer of splenocytes from a tolerant chimeric recipient to a naive recipient did not result in rejection. These experiments suggested that na€ ıve donor T cells were important at early phases in the CY-induced tolerance system. Subsequent studies showed that, although adoptive transfer of spleen cells from an old chimera to a naive recipient results in permanent acceptance of a skin allograft, the acceptance was cancelled by CD4 + T-cell depletion, showing that CD4 + Tregs are responsible for late tolerance of the CY-induced tolerance system. 40 Other preclinical studies have reported that the absence of Foxp3 + Tregs abrogates GVHD protection provided in CY-induced tolerance. 41 This conclusion is compatible with recent observations that Tregs are critical for tolerance induction. [42] [43] [44] We would like to explain the mechanism of Tregs inducing suppression here, because Tregs are the most widely and generally recognized cell type for induction of transplant tolerance including the CY-induced tolerance system. Tregs are defined as thymic-derived Tregs or peripherally-derived Tregs. Thymic-derived Tregs and peripherally-derived Tregs can be distinguished by different soluble factors and cell surface markers. Notably, intranuclear Foxp3 is thought to be the most specific marker for Tregs. 43, 44 The suppressive mechanisms of Tregs are divided into three parts as follows: (i) inhibitory factor release; (ii) cytokines; and (iii) blockage of dendric cells functions. 43, 44 Tregs also inhibit anti-donor reactions by perforin and granzymeA. 45 Furthermore, through deletion of IL-2, Tregs cause metabolic dysregulation of activated CD8 and CD4 T cells. 46, 47 Because Tregs are considered to be important for tolerance induction, it has been reported that 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester-labeled Tregs migrate into transplanted grafts and survival is prolonged in tolerant mice. 48 Another group reported that adoptive transfer of intragraft Tregs might be important for induction of tolerance. 49 Therefore, Tregs are essential for immunological tolerance. Importantly, the situation in the CY-induced tolerance system is the same. Kankry et al. reported the importance of Tregs in the PTCY system. 38 They reported that although the patients showed significant reductions in na€ ıve alloreactive CD4 + T cells, memory CD4 + Foxp3 + T cells were preserved. In particular, effector Tregs recovered rapidly after BMT and CY administration, and they were dominantly present in patients with GVHD. In addition, they considered that the high levels of aldehyde dehydrogenase were the major mechanism of CY resistance. Taken together, the report showed that resistance of Tregs against CY through expression of aldehyde dehydrogenase might contribute to the clinical activity of PTCY in preventing GVHD and inducing tolerance. Conversely, CY administration has recently been suggested to have a specific effect on depleting Tregs. 50 Therefore, we investigated whether CY reduces CD4 + CD25 + Foxp3 + Tregs compared with CD4 + CD25 + Foxp3 À T cells in our non-myeloablative SCT system. 32 We found that this system did not promote immunological tolerance, but we hypothesized that it is important to establish chimerism. Further studies are required to test this hypothesis.
Furthermore, as another cell subset related to the CYinduced tolerance system, we would like to introduce NK T cells. Hongo et al. 
Clinical application of CY-induced tolerance Clinical application to hematological malignancies
To understand the CY-induced tolerance in kidney transplantation, we need to know the history of the clinical application to hematological malignancies. The CY-induced tolerance system has been evaluated in the aforementioned preclinical models. Based on our and other preclinical results, some pilot trials of haploidentical BMT to treat hematological malignancies were started in 1999. The conditioning regimen was based on the non-ablative regimen of Flu and low-dose TBI. 52 To prevent GVHD, CY was given at 3 days after BMT, together with a calcineurin inhibitor, tacrolimus and MMF. After some experimentation, a total dose of 29 mg/kg CY administered on days À5 and À6 was added to the conditioning regimen. Because grafts were successfully established in eight of 10 patients, the CY dose was fixed for the next phase II trial. Although the outcomes of the first 13 patients were published in 2002, phase II trials of haploidentical BMT using post-transplantation CY had been continued after the first publication. 53 Outcomes of 68 patients in phase II trials were reported in 2008. 54 According to the report, the administered CY amount was modified in the regimen by increasing the total dose of post-transplantation CY to 100 mg/kg administered over days +3 and +4, resulting in a decrease in the incidence of GVHD. The median time of hematopoietic recovery (neutrophils and platelets) was 15 and 24 days, respectively. Primary graft loss occurred in 13% of total patients, and autologous hematopoiesis failed to occur in one patient, resulting in a fatality by infection. Conversely, there was a significant difference in the incidence of chronic GVHD among recipients of two versus one injection of posttransplantation CY (5% vs 25%). After this report, CY administration for 2 days in a row before BMT had become standard.
After the trials, multicenter trials of MHC-identical BMT (the Bone Marrow Transplant Clinical Trials Network 603; CTN 0603) were carried out. The reduced intensity conditioning consisted of Flu, CY and 2 Gy TBI, although the dosing of Flu and CY differed slightly between the trials. The outcomes of the trials were published in 2011. 55 In the trials, the survival rate at 6 months exceeded the 60% reported for unrelated donors. The incidence of grade II-IV acute GVHD and chronic GVHD was 32% and 13%, respectively, after BMT. Although the incidence of chronic GVHD was relatively high, it was almost the same rate as that in the previous trials. 56, 57 According to these results, the ratio of acute GVHD in PTCY is considered to be relatively acceptable. One of the reasons was reported by Roberto et al. 37 They reported that T memory stem cells, which show a superior reconstitution capacity in preclinical models, are the most enriched circulating T-cell subset in the early days after haploidentical transplantation combined with PTCY. Because transferred naive memory cells (not T memory stem cells) showed longer survival against CY, they suggested that post-transplantation T memory stem cells originated from naive precursors. Donor naive T cells specific for various antigens present in the recipient were considered to contribute to peripheral reconstitution by differentiation to effector T cells. They concluded that the abundance of na€ ıve T cells in bone marrow correlated with improved overall survival and decreased acute GVHD. 58 Furthermore, T-cell depletion in vivo and irradiation have been thought to be important for the induction of tolerance and prevention of GVHD. Deletion of memory T cells and inhibition of T-cell activation are reported to be important for induction of transplantation tolerance. 59 Non-selective depletion of T cells is carried out by either monoclonal antibodies, such as anti-CD3 and anti-CD52, or polyclonal ATG. Recipients with the depletive protocols were reported to be protected against GVHD because immunodepletive agents control graft-derived alloreactive T cells. 60 Conversely, preparative irradiation including TBI is a well-established approach for conditioning patients with leukemia and organs dysfunction (before transplantation) for hematopoietic SCT. Developments and improvements in conditioning regimens, TBI techniques, and patient care with transplantation have led to better outcomes and longer patient survival. 60 
Clinical application to kidney transplantation
The Massachusetts General Hospital research group first reported a pilot trial of combined HLA-matched bone marrow and kidney transplantation for patients with multiple myeloma and severe renal dysfunction. [61] [62] [63] A total of 10 patients received a combined transplantation from HLA-matched related donors. As a result, there has been no transplantationrelated mortality. Although six patients were alive and healthy, among the other four patients, two received a second BMT from their original donor because of progression of their myeloma. Researchers at the Massachusetts General Hospital extended this study to HLA-mismatched combinations. They reported stable renal allograft functions for over 3 years after withdrawal of immunosuppressive drugs in four recipients. 14, 64 However, nine patients were reported to develop graft dysfunction soon after transplantation. Furthermore, severe acute tubular and glomerular endothelial injuries were observed in renal biopsies by electron microscopy. After the pilot studies, they received PTCY-based regimens based on studies from Hadassah University and Johns Hopkins University. 54, 65 Haploidentical hematopoietic SCT has become the standard for patients who lack fully matched related donors. 65 They initially designed a reduced intensity conditioning regimen of rabbit ATG, low-dose CY, and 200-cGy TBI before simultaneous kidney transplantation and BMT on day 0, which was then followed by PTCY, tacrolimus and MMF. The first enrolled patient was a 67-year-old woman with severe renal dysfunction as a result of myeloma kidney. Although >38 months had passed after transplantation with no evidence of recurrent myeloma and normal renal functions, she could not be weaned off tacrolimus because of hematopoietic graft rejection.
The second patient was a 57-year-old women with severe renal dysfunction as a result of myeloma kidney. Two years had passed after transplantation with no evidence of recurrent myeloma or GVHD, and normal renal functions, and she was weaned off immunosuppressive agents at approximately 8 months after transplantation. The third patient was a 38-year-old men with recurrence of non-Hodgkin lymphoma and severe renal dysfunction. At 10 days after transplantation, his mental status was altered and he underwent progressive neurological decline at 6 months after transplantation. As a result, the third patient died. Considering the catastrophic toxicities and death of the third patient, they modified the regimen as shown in Figure 4a. 14 The fourth patient was a 52-year-old man with severe renal dysfunction as a result of myeloma kidney. He received the modified regimen. His transplant course was fairly uncomplicated with full donor engraftment, normal renal functions and no GVHD. At 6 months after transplantation, he was healthy and weaned off immunosuppressive agents.
The Northwestern University research group developed CY-based renal transplantation using FCs. In their study, we consider that FCs had a major role in establishing tolerance. FCs are identified as CD8-positive and abcd TCR-negative donor bone marrow-derived cells that promote allogeneic stem cell reconstitution. As a result of FC infusion, complete MHC barriers were overcome without clinical or histological GVHD. 64, 66, 67 The functions and surface markers of FCs are distinct from those of stem cells. Previous reports have shown that FC infusion leads to enhancement of Tregs responses that are associated with tolerance induction after transplantation. 67 The Northwestern University research group applied HLA-mismatched combined SCT and kidney transplantation from related and unrelated donors for the treatment of renal failure. 17 Eight patients received a CY, Flu and lowdose TBI preparative regimen. FCs were administrated at 1 day after kidney transplantation. Furthermore, on day 3, post-transplantation high-dose CY was administered to deplete alloreactive donor T cells. Tacrolimus and MMF were administered and maintained to avoid additional GVHD (Fig. 4b) . Two patients with transient chimerism were maintained by tacrolimus monotherapy, while one patient had renal artery thrombosis and viral sepsis. They reported stable renal allograft functions and complete chimerism in five patients without immunosuppressive agents. These were the first reports to show durable and stable chimerism and tolerance without immunosuppressive agents after combined HLA-mismatched hematopoietic SCT and kidney transplantation from the same donor. In addition, the research group reported the original eight patients plus another seven recipients with combined kidney transplantation and SCT. 18 All recipients were HLA-disparate from their living kidney/hematopoietic stem cell donors, ranging from five of six matched related donors to zero of six matched unrelated donors. As the results, nine patients showed full chimerism, while six of these patients were successfully weaned off immunosuppressive agents and two patients were tapered off immunosuppressive agents. Because one patient showed kidney graft loss caused by an atypical viral infection, they received a second transplantation. Because five patients showed transient or mixed chimerism, they could not be weaned off immunosuppressive agents. Only one patient had complete rejection of bone marrow engraftment. Only one patient with transient or mixed chimerism was weaned off immunosuppression. Consequently, 10 of the 15 patients were successfully withdrawn or withdrawing from their immunosuppressive status. Although tolerance might not be induced by CY, but by FCs, these results are interesting. Because the observation period was short, we believe that further and careful observations are required.
Although tolerance is not induced by CY, the Stanford University group published a clinical pilot trial examining combined transplantation of donor mobilized peripheral blood mononuclear cells/bone marrow and a donor kidney for tolerance induction. 17, 18 In the report, 16 patients received total lymphoid irradiation and ATG before kidney transplantation. They were injected with CD34
+ hematopoietic precursor cells and T cells from HLA identical donors for the tolerance induction protocol (Fig. 4c) . Donor CD34 + cells and T cells were intravenously injected on day 11. All patients were provided with a post-transplantation immunosuppressive regimen that included MMF for 1 month and cyclosporine for at least 6 months starting at day 0. Patients were weaned off cyclosporine when there was no evidence of clinical rejection. However, surveillance biopsies were considered to be important. Cyclosporine withdrawal was delayed in patients with mixed chimerism to confirm that there was no sign of graft rejection. Eight of the 16 patients showed long-term chimerism for 6 months or longer and were successfully withdrawn from immunosuppressive agents, and four were being tapered. 17, 18 Just four patients were not weaned off immunosuppressive agents because of rejection signs. 15, 16 Therefore, the majority of patients with transplantations from HLA-matched donors were successfully weaned off immunosuppressive agents, and all patients had excellent graft functions. However, in their previous study, all four patients could not be weaned off immunosuppressive drugs in the HLA-mismatched condition. 68 We hypothesized that the perfect tolerance induction was difficult by using only immunosuppressive agents without CY.
Conclusion
Combined bone marrow and kidney transplantations have shown efficacy and safety, as well as the proof-of-principle of inducing tolerance after HLA-matched and -mismatched renal transplantation. Furthermore, many studies of renal transplantation using the CY-induced tolerance system have shown that Tregs and NK T cells play important roles. Our group has examined the CY-induced tolerance system for many years. This system has been modified and the name has been changed to the PTCY system. Recently, some reports have shown that, although perfect immunological tolerance is not induced, more than approximately two-thirds of patients can be withdrawn from immunosuppressive agents without GVHD. We have considered clinical application of immunological tolerance by CY in Japan. Expanding the immune features of our system and renal transplant tolerance are important steps for successful clinical application and evaluation of withdrawing immunosuppressive agents. Several clinical trials have been proposed to further expand the application of tolerance approaches. These approaches include widening the eligibility for combined transplantations to patients with other hematological disorders associated with renal failure, such as sickle-cell disease, and extending tolerance approaches to other organs and tissues. We believe that a protocol for a tolerance-inducing system has the potential to improve the quality of life of recipients by decreasing the side-effects of immunosuppressive agents. Such protocols could also reduce healthcare costs by eliminating the considerable costs of these drugs.
